[HTML][HTML] Development of a physiologically based pharmacokinetic model for tegoprazan: application for the prediction of drug–drug interactions with CYP3A4 …
LT Ngo, J Lee, H Yun, J Chae - Pharmaceutics, 2023 - mdpi.com
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators.
LT Ngo, J Lee, H Yun, J Chae - Pharmaceutics, 2023 - search.ebscohost.com
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators.
LT Ngo, J Lee, HY Yun, JW Chae - Pharmaceutics, 2023 - europepmc.org
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
LT Ngo, J Lee, H Yun, C Jung-woo - Pharmaceutics, 2023 - search.proquest.com
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators
LT Ngo, J Lee, HY Yun, JW Chae - Pharmaceutics, 2023 - pubmed.ncbi.nlm.nih.gov
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
[引用][C] Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of DrugDrug Interactions with CYP3A4 …
LT Ngo, J Lee, H Yun, J Chae - Pharmaceutics (Web), 2023 - jglobal.jst.go.jp
Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan:
Application for the Prediction of DrugDrug Interactions with CYP3A4 Perpetrators | Article …
Application for the Prediction of DrugDrug Interactions with CYP3A4 Perpetrators | Article …
[HTML][HTML] Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 …
LT Ngo, J Lee, H Yun, J Chae - Pharmaceutics, 2023 - ncbi.nlm.nih.gov
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …
Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter …